-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Earnings Call Summary | Applied DNA Sciences(APDN.US) Q1 2024 Earnings Conference
Earnings Call Summary | Applied DNA Sciences(APDN.US) Q1 2024 Earnings Conference
The following is a summary of the Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript:
Financial Performance:
Applied DNA sciences reported a drop in total revenues for Q1 2024 to approximately $891,000, a decrease from the same period in the previous fiscal year due to lower clinical laboratory service revenues and product revenues.
Gross profit was $231,000, a reduction from the prior fiscal year period.
Operating expenses for Q1 2024 increased by $424,000 to $4 million in comparison to the prior fiscal year.
Operating loss increased to $3.8 million in Q1 2024, a noticeable raise from the prior fiscal period.
The company's cash equivalents went down to $3.4 million by the end of the year, compared to $7.2 million at the end of September 2023.
Business Progress:
Threatening cash position was addressed through a registered direct public offering fetching gross proceeds of approximately $3.4 million.
Their prime focus is on the commercialization of Linea IVT and Linea DNA platforms and the company is working towards leaner organization structure.
The company expects significant revenue generation from the GMP facility, which is estimated to generate about $15 million annually.
They are accelerating the commercialization of Linea IVT, providing critical starting materials for mRNA therapeutics and transitioning the manufacturing capacity to multigram scale GMP orders.
The company achieved milestones like successfully executing customers' evaluations for Linea IVT platforms and expects the GMP facility to operate by H1 calendar 2024.
In the future, they aim to establish long-term supply agreements and partner with various Contract Development and Manufacturing Organizations.
They are currently manufacturing clinical materials for trials in China and Australia and have seen rapid adoption of the Linea IVT platform since its launch in August 2023.
More details: Applied DNA Sciences IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
The following is a summary of the Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript:
以下是应用DNA科学公司(APDN)2024年第一季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
Applied DNA sciences reported a drop in total revenues for Q1 2024 to approximately $891,000, a decrease from the same period in the previous fiscal year due to lower clinical laboratory service revenues and product revenues.
Gross profit was $231,000, a reduction from the prior fiscal year period.
Operating expenses for Q1 2024 increased by $424,000 to $4 million in comparison to the prior fiscal year.
Operating loss increased to $3.8 million in Q1 2024, a noticeable raise from the prior fiscal period.
The company's cash equivalents went down to $3.4 million by the end of the year, compared to $7.2 million at the end of September 2023.
应用DNA科学报告称,由于临床实验室服务收入和产品收入减少,2024年第一季度的总收入下降至约89.1万美元,较上一财年同期有所下降。
毛利为23.1万美元,比上一财年有所减少。
与上一财年相比,2024年第一季度的运营支出增加了42.4万美元,达到400万美元。
2024年第一季度的营业亏损增至380万美元,比上一财年大幅增加。
截至年底,该公司的现金等价物降至340万美元,而2023年9月底为720万美元。
Business Progress:
业务进展:
Threatening cash position was addressed through a registered direct public offering fetching gross proceeds of approximately $3.4 million.
Their prime focus is on the commercialization of Linea IVT and Linea DNA platforms and the company is working towards leaner organization structure.
The company expects significant revenue generation from the GMP facility, which is estimated to generate about $15 million annually.
They are accelerating the commercialization of Linea IVT, providing critical starting materials for mRNA therapeutics and transitioning the manufacturing capacity to multigram scale GMP orders.
The company achieved milestones like successfully executing customers' evaluations for Linea IVT platforms and expects the GMP facility to operate by H1 calendar 2024.
In the future, they aim to establish long-term supply agreements and partner with various Contract Development and Manufacturing Organizations.
They are currently manufacturing clinical materials for trials in China and Australia and have seen rapid adoption of the Linea IVT platform since its launch in August 2023.
通过注册的直接公开募股解决了威胁性的现金状况,总收益约为340万美元。
他们的主要重点是Linea IVT和Linea DNA平台的商业化,该公司正在努力实现更精简的组织结构。
该公司预计,该GMP设施将产生可观的收入,估计每年将产生约1500万美元的收入。
他们正在加速Linea IVT的商业化,为mRNA疗法提供关键的起始材料,并将制造能力过渡到多克规模的GMP订单。
该公司实现了里程碑,例如成功执行了客户对Linea IVT平台的评估,并预计该GMP设施将在2024年上半年投入运营。
将来,他们的目标是建立长期供应协议,并与各种合同开发和制造组织合作。
他们目前正在为中国和澳大利亚的试验生产临床材料,自2023年8月推出Linea IVT平台以来,该平台已迅速得到采用。
More details: Applied DNA Sciences IR
更多详情: 应用 DNA 科学 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧